[1] Xie Y. Hepatitis B Virus-Associated Hepatocellular Carcinoma. ADV EXP MED BIOL. 2017; 1018: 11-21.
[2][Strategies of primary prevention of liver cancer in China: expert consensus (2018)]. Zhonghua Yu Fang Yi Xue Za Zhi. 2019; 53: 36-44.
[3] Gomaa AI. Recent advances in multidisciplinary management of hepatocellular carcinoma. World Journal of Hepatology. 2015; 7: 673.
[4] Chen Q, Wu P, Huang T, Shen L, Huang Z, Li W. Efficacy of treatment regimens for advanced hepatocellular carcinoma. MEDICINE. 2019; 98: e17460.
[5] Veltri KL, Espiritu M, Singh G. Distinct genomic copy number in mitochondria of different mammalian organs. J CELL PHYSIOL. 1990; 143: 160-4.
[6] Xiong Y, Lu QJ, Zhao J, Wu GY. Metformin inhibits growth of hepatocellular carcinoma cells by inducing apoptosis via mitochondrion-mediated pathway. Asian Pac J Cancer Prev. 2012; 13: 3275-9.
[7] Dilip A, Cheng G, Joseph J, et al.. Mitochondria-targeted antioxidant and glycolysis inhibition: synergistic therapy in hepatocellular carcinoma. Anticancer Drugs. 2013; 24: 881-8.
[8] Wenceslau CF, McCarthy CG, Szasz T, Spitler K, Goulopoulou S, Webb RC. Mitochondrial damage-associated molecular patterns and vascular function. EUR HEART J. 2014; 35: 1172-7.
[9] Reznik E, Miller ML, Senbabaoglu Y, et al.. Mitochondrial DNA copy number variation across human cancers. ELIFE. 2016; 5.
[10] Fliss MS, Usadel H, Caballero OL, et al.. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. SCIENCE. 2000; 287: 2017-9.
[11] Bao D, Ba Y, Zhou F, et al.. Alterations of telomere length and mtDNA copy number are associated with overall survival in hepatocellular carcinoma patients treated with transarterial chemoembolization. CANCER CHEMOTH PHARM. 2016; 78: 791-9.
[12] Yu M. Circulating cell-free mitochondrial DNA as a novel cancer biomarker: opportunities and challenges. MITOCHONDR DNA. 2012; 23: 329-32.
[13] Li L, Hann H, Wan S, et al.. Cell-free circulating mitochondrial DNA content and risk of hepatocellular carcinoma in patients with chronic HBV infection. SCI REP-UK. 2016; 6.
[14] Weerts M, Timmermans EC, van de Stolpe A, et al.. Tumor-Specific Mitochondrial DNA Variants Are Rarely Detected in Cell-Free DNA. NEOPLASIA. 2018; 20: 687-96.
[15] Fu X, Wan S, Hann HW, et al.. Relative telomere length: a novel non-invasive biomarker for the risk of non-cirrhotic hepatocellular carcinoma in patients with chronic hepatitis B infection. EUR J CANCER. 2012; 48: 1014-22.
[16] Wan S, Hann HW, Myers RE, et al.. Telomere length in circulating serum DNA as a novel non-invasive biomarker for cirrhosis: a nested case-control analysis. LIVER INT. 2012; 32: 1233-41.
[17] Ellinger J, Muller DC, Muller SC, et al.. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies. Urol Oncol. 2012; 30: 509-15.
[18] Mahmoud EH, Fawzy A, Ahmad OK, Ali AM. Plasma Circulating Cell-free Nuclear and Mitochondrial DNA as Potential Biomarkers in the Peripheral Blood of Breast Cancer Patients. Asian Pac J Cancer Prev. 2015; 16: 8299-305.
[19] Meng X, Schwarzenbach H, Yang Y, et al.. Circulating Mitochondrial DNA is Linked to Progression and Prognosis of Epithelial Ovarian Cancer. TRANSL ONCOL. 2019; 12: 1213-20.
[20] Raoul J, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. CANCER TREAT REV. 2019; 72: 28-36.
[21] Meng M, Wen Q, Cui Y, She B, Zhang R. Meta-analysis: Traditional Chinese Medicine for Improving Immune Response in Patients With Unresectable Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization. EXPLORE. 2011; 7: 37-43.
[22] Jia W, Wang L. Using Traditional Chinese Medicine to Treat Hepatocellular Carcinoma by Targeting Tumor Immunity. Evid Based Complement Alternat Med. 2020; 2020: 9843486.
[23] Tang CW, Zhu M, Feng WM, Bao Y, Zheng YY. Chinese herbal medicine, Jianpi Ligan decoction, improves prognosis of unresectable hepatocellular carcinoma after transarterial chemoembolization: a retrospective study. Drug Des Devel Ther. 2016; 10: 2461-6.